Security
ADTX · Aditxt, Inc.
ADTXOTCCommon stockCurrentCIK 1726711Updated Sep 25, 2026
Name history
ADiTx Therapeutics, Inc. · through Jul 6, 2021Aditx Therapeutics, Inc. · through Jul 6, 2021
ADTX price & chart
Loading TradingView…
OTC:ADTX on TradingView ↗About the company
Aditxt, Inc. (NASDAQ: ADTX) is a public company focused on developing and commercializing health innovation platforms. Ignite Proteomics is currently a 100%-owned subsidiary of Aditxt. Through the proposed business combination, Aditxt expects to unlock value in Ignite at an implied equity value of approximately $150 million, while Ignite is expected to become an independent publicly traded company. Aditxt is expected to continue as a separate Nasdaq-listed public company, subject to continued compliance with Nasdaq listing requirements.
In the news
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting News provided by Evofem Biosciences, Inc. Sep 09, 2025, 09:28 ET Share this article Share to X Share this article Share to X -- Special Meeting to be held on September 26, 2025 -- SAN DIEGO , Sept. 9, 2025 /PRNewswire/ ↗
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Other Events
Items 8.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
SCHEDULE 13G/A - filed by Castillo Christopher regarding Aditxt, Inc.
SCHEDULE 13G - filed by Castillo Christopher regarding Aditxt, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 16,516,781Source | 32,144,390Source | 44,578,327Source | 10,735,249Source |
| Property, Plant and Equipment, NetUSD | 880,241Source | 1,547,774Source | 1,898,243Source | 2,318,863Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,778Source | 6,111Source | 9,444Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 833,031Source | 97,102Source | 2,768,640Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 43,435Source | — | 527,961Source |
| Inventory, NetUSD | 5,774Source | 11,245Source | 745,502Source | — |
| Assets, CurrentUSD | 3,821,735Source | 1,999,841Source | 6,912,948Source | 4,743,563Source |
| Operating Lease, Right-of-Use AssetUSD | 1,204,526Source | 1,225,781Source | 2,200,299Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,563,099Source | 23,857,994Source | 28,531,558Source | 5,528,942Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 412Source | 130Source | 1,319Source | 4,307Source |
| Additional Paid in CapitalUSD | 214,365,470Source | 168,792,592Source | 143,997,710Source | 100,443,967Source |
| Retained Earnings (Accumulated Deficit)USD | -209,808,770Source | -168,094,569Source | -127,741,072Source | -95,040,362Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,254,170Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 5,609,704Source | 496,576Source | 16,056,377Source | 5,206,307Source |
| Liabilities and EquityUSD | 16,516,781Source | 32,144,390Source | 44,578,327Source | 10,735,249Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 12,220,193Source | 23,407,123Source | 25,889,814Source | 3,643,724Source |
| Operating Lease, Liability, CurrentUSD | 808,179Source | 683,352Source | 999,943Source | — |
| Accounts Payable, CurrentUSD | 7,340,490Source | 10,192,373Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 342,904Source | 436,354Source | 1,041,744Source | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,656,022Source | -583,180Source | -9,608Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 300,041Source | 1,889,527Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -42,787,043Source | -35,020,058Source | -32,390,447Source | -27,649,876Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 473,311Source | 33,071Source | 1,402,018Source | 3,131,368Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -43,435Source | -364,891Source | -119,635Source | 36,767Source |
| Increase (Decrease) in InventoriesUSD | -5,471Source | -734,257Source | -204,591Source | 455,396Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -25,688,359Source | -16,762,121Source | -18,576,811Source | -22,392,006Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,438,743Source | -5,000,000Source | -14,407Source | -241,918Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 13,743Source | — | 14,407Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 30,492,670Source | 22,498,050Source | 15,919,680Source | 17,530,503Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | -5,103,421Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,198,599Source | 833,031Source | 97,102Source | 2,768,640Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,465,546Source | 1,235,640Source | 2,726,020Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 507,558Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 1,533,048Source |
| Amortization of Intangible AssetsUSD | 3,333Source | 3,333Source | 107,556Source | 107,000Source |
| DepreciationUSD | 269,271Source | 613,918Source | 435,027Source | 428,977Source |
| Gain (Loss) on Disposition of AssetsUSD | — | -3,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 51,712Source | — |
| General and Administrative ExpenseUSD | 15,974,863Source | 16,286,216Source | 18,607,142Source | 15,985,552Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 13,499,811Source |
| InterestExpenseNonoperatingUSD | 681,156Source | 4,188,725Source | — | — |
| Investment Income, InterestUSD | 200,179Source | 1,454Source | — | 57,348Source |
| Net Income (Loss) Attributable to ParentUSD | -43,101,451Source | -40,353,497Source | -32,380,839Source | -27,649,876Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -1,072,842Source | -573,572Source | -9,608Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -32,700,710Source | -27,612,199Source |
| Nonoperating Income (Expense)USD | -23,216,319Source | -7,156,360Source | -6,328,022Source | — |
| Operating ExpensesUSD | 19,570,992Source | 27,370,209Source | 25,950,765Source | 25,647,034Source |
| Operating Lease, ExpenseUSD | — | — | 1,140,949Source | 1,396,875Source |
| Other Operating Income (Expense), NetUSD | — | 8,100,000Source | — | — |
| Payments of Financing CostsUSD | — | — | 262,160Source | 400,491Source |
| Payments to Acquire InvestmentsUSD | — | 5,000,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 11,054,883Source | 17,233,307Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 179,419Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | 826,795Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 23,766,209Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,195Source | 133,985Source | 645,176Source | 933,715Source |
| Cost of RevenueUSD | — | — | — | 766,779Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | 1,849,460Source |
| Operating Income (Loss)USD | -19,570,724Source | -27,863,698Source | -26,062,425Source | -25,480,098Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -42,787,043Source | -35,020,058Source | -32,390,447Source | -27,649,876Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -1,072,842Source | -573,572Source | -9,608Source | — |
| Net Income (Loss) Attributable to ParentUSD | -43,101,451Source | -40,353,497Source | -32,380,839Source | -27,649,876Source |
| Earnings Per Share, BasicUSD per share | -1,153.83Source | -3,062.51Source | -108.15Source | -14.89Source |
| Earnings Per Share, DilutedUSD per share | -1,153.83Source | -3,062.51Source | -108.15Source | -14.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 37,355Source | 13,177Source | 302,356Source | 1,854,724Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 37,355Source | 13,177Source | 302,356Source | 1,854,724Source |
| Interest Expense (non-operating)USD | 681,156Source | 4,188,725Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 3,333Source | 3,333Source | 107,556Source | 107,000Source |
| Business Combination, Acquisition Related CostsUSD | — | 1,008,669Source | — | — |
| General and Administrative ExpenseUSD | 15,974,863Source | 16,286,216Source | 18,607,142Source | 15,985,552Source |
| Gross ProfitUSD | 268Source | -493,489Source | -111,660Source | 166,936Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 42,787,000Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 13,499,811Source |
| Interest Expense, DebtUSD | — | — | — | 0Source |
| Interest Income, OtherUSD | — | — | 10,166Source | — |
| Investment Income, InterestUSD | 200,179Source | 1,454Source | — | 57,348Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -32,700,710Source | -27,612,199Source |
| Nonoperating Income (Expense)USD | -23,216,319Source | -7,156,360Source | -6,328,022Source | — |
| Operating ExpensesUSD | 19,570,992Source | 27,370,209Source | 25,950,765Source | 25,647,034Source |
| Operating Lease, ExpenseUSD | — | — | 1,140,949Source | 1,396,875Source |
| Other ExpensesUSD | — | — | — | 2,169,778Source |
| Other General and Administrative ExpenseUSD | — | — | 1,843,902Source | 105,049Source |
| Other IncomeUSD | — | — | — | 58,960Source |
| Other Operating Income (Expense), NetUSD | — | 8,100,000Source | — | — |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | 319,871Source | — |
| Research and Development ExpenseUSD | 3,194,133Source | 10,886,130Source | 7,074,339Source | 7,268,084Source |
| Selling and Marketing ExpenseUSD | 401,996Source | 197,863Source | 269,284Source | — |
| Selling ExpenseUSD | — | — | 1,800,000Source | — |
Offerings
Registration 333-288211
Filing attachments
ea030577601ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Delisting of Securities of Aditxt, Inc. from The Nasdaq Stock Market NEW YORK, September 17, 2026 - The Nasdaq Stock Market announced today that it will delist the common stock of Aditxt, Inc. Aditxt, Inc.’s common stock was suspended on June 25, 2026 and has not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after the Form 25 is filed. For news and additio…
Read attachment ↗ea029578801ex99-1.htm · 8-K · 2026-06-24
EX-99.1 2 ea029578801ex99-1.htm NASDAQ HEARINGS PANEL NOTICE, DATED JUNE 23, 2026 Exhibit 99.1 Sent via electronic delivery June 23, 2026 Keely Moxley Donohoe Advisory Associates LLC 9801 Washingtonian Blvd Ste 340 Gaithersburg, MD 20878 RE: Aditxt, Inc. (Symbol: ADTX) Nasdaq Listing Qualifications Hearings Docket No. NQ 7352C-26 Dear Ms. Moxley: The Nasdaq Hearings Panel (the “Panel) has determined to deny the request of Aditxt, Inc. (the “Company”) to …
Read attachment ↗ea029430701ex99-1.htm · 8-K · 2026-06-10
EX-99.1 6 ea029430701ex99-1.htm PRESS RELEASE, DATED JUNE 9, 2026 Exhibit 99.1 Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million Transaction values Ignite Proteomics at approximately $150 million and is expected to position Ignite as an independent NYSE-listed functional proteomics company, while Aditxt continues as a separate Nasdaq-listed company MOUNTAIN VIEW, CA, GOLDEN, CO and HONG KONG - June 9, 2026 - Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”),…
Read attachment ↗ea029290201ex99-1.htm · 8-K · 2026-06-01
EX-99.1 2 ea029290201ex99-1.htm PRESS RELEASE OF ADITXT, INC., DATED JUNE 1, 2026 Exhibit 99.1 ADITXT, INC. (NASDAQ: ADTX) PRESS RELEASE FOR IMMEDIATE RELEASE Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders Seasoned executive who founded and built a NYSE-listed healthcare real estate company to over $1 billion in enterprise value - delivering an average dividend yield…
Read attachment ↗ea029070701ex99-1.htm · 8-K · 2026-05-15
EX-99.1 3 ea029070701ex99-1.htm PRESS RELEASE DATED MAY 14, 2026 Exhibit 99.1 Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026 Mountain View, Ca. (May 14, 2026) - Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-27 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq …
Read attachment ↗ea028531901ex99-1.htm · 8-K/A · 2026-04-07
EX-99.1 3 ea028531901ex99-1.htm AUDITED FINANCIAL STATEMENTS OF IGNITE PROTEOMICS LLC AS OF DECEMBER 31, 2025 AND 2024 AND FOR THE YEAR ENDED DECEMBER 31, 2025 AND THE PERIOD FROM MAY 30, 2024 (INCEPTION) THROUGH DECEMBER 31, 2024 Exhibit 99.1 Ignite Proteomics LLC Financial Statements For the Year Ended December 31, 2025 and for the Period from May 30, 2024 (Inception) to December 31, 2024 IGNITE PROTEOMICS LLC TABLE OF CONTENTS …
Read attachment ↗